MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Exosomes from patients with Parkinson’s disease are pathological in mice

    C. Han, N. Xiong, X. Guo, J. Huang, K. Ma, L. Liu, Y. Xia, S. Yin, L. Kou, F. Wan, J. Hu, G. Zhang, T. Wang (Wuhan, China)

    Objective: To verify the hypothesis that serum-derived exosomes from patients with Parkinson’s disease (PD) may serve as risk carriers for inter-neuronal risk transmission, eventually resulting…
  • 2019 International Congress

    Applicability of modified definition of Vascular Parkinsonism in patients with Parkinsonism attending outpatient department: A tertiary care hospital-based study in south India

    S. Jaiswal (Hyderabad, India)

    Objective: This study aims to assess the applicability of modified Vascular Parkinsonism (VP) criteria in outpatient department in a tertiary care hospital in south India.…
  • 2019 International Congress

    123I-FP-CIT SPECT imaging in early PD patients versus mid and late onset PD: Longitudinal data from the PPMI study

    C. Koros, A. Simitsi, M. Stamelou, A. Prentakis, A. Bougea, I. Pachi, D. Papadimitriou, I. Beratis, N. Papagiannakis, E. Angelopoulou, S. Papageorgiou, X. Geronicola Trapali, L. Stefanis (Athens, Greece)

    Objective: To determine whether there are longitudinal differences in dopaminergic denervation [as exemplified by signal reduction in 123I-FP-CIT SPECT] in early PD patients versus mid…
  • 2019 International Congress

    Case-control study of risk developing parkinsonism in Alzheimer’s disease in relation to hypertension, dyslipidemia, and diabetes in Taiwan

    W. Lin, PY. Chiu (Changhua, Taiwan)

    Objective: To clarify the relationship between vascular risk factors and parkinsonism in Alzheimer’s disease Background: This case-control study investigated the associations of a history of…
  • 2019 International Congress

    Memantine and 3D gait analysis in patient with Parkinson’s disease: an observer-blind randomized clinical trial

    I. Miliukhina, E. Gracheva (Saint-Petersburg, Russian Federation)

    Objective: To examine the efficacy of memantine (20 mg), a non-competitive NMDAR antagonist, in the treatment of gait impairment in PD patients with mild cognitive…
  • 2019 International Congress

    Multiple system atrophy with predominant striato-nigral degeneration (MSA-P) and TDP-43 pathology: an unusual pathologic variant of MSA

    L. Nwabuobi, D. Tomishon, N. Shneider, S. Fahn, J. Vonsattel, E. Cortes (New York, NY, USA)

    Objective: To report a patient with MSA with concomitant occurrence of TDP-43-labeled and a-synuclein labeled inclusions in oligodendrocytes. Background: The pathologic hallmark in multiple system atrophy…
  • 2019 International Congress

    The Progressive Supranuclear Palsy Functional Disability Scale: Sensitivity to change

    I. Piot, K. Schweyer, G. Respondek, M. Grimm, M. Stamelou, P. Sckopke, T. Schenk, C. Goetz, G. Stebbins, G. Höglinger (Munich, Germany)

    Objective: To determine the sensitivity to change within 12 months as well as completion time of the Progressive Supranuclear Palsy Functional Disability Scale (PSPFDS). Background:…
  • 2019 International Congress

    Early stage Parkinson’s disease patients with GBA mutation have more severe motor symptoms and difficult to differentiate in routine clinical practice

    S. Abe, K. Komatsu, H. Satoi, H. Saiki, Y. Oka (Osaka, Japan)

    Objective: The objective of this study is to compare clinical features of early stage of Parkinson’s disease (PD) between with and without positive glucocerebrosidase (GBA)…
  • 2019 International Congress

    THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)

    S. Shrewsbury, J. Campbell, M. Swardstrom, A. Lehn, K. Satterly, J. Hoekman (Seattle, WA, USA)

    Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuatedPrecision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid…
  • 2019 International Congress

    Medical and Device-Guided Therapies and Deep Brain Stimulation in Parkinson’s disease: Experience of a Tertiary Centre from Turkey

    Y. Sucullu Karadag, D. Divanlıoglu, E. Kocabicak, N. Subutay Oztekin, D. Belen (Ankara, Turkey)

    Objective: This study is aimed to investigate the clinical and therapeutic data of PD patients who have been evaluated at a dedicated-weekly Movement Disorders Clinic. Details…
  • « Previous Page
  • 1
  • …
  • 210
  • 211
  • 212
  • 213
  • 214
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley